Main Article Content

Abstract

The study was done after obtaining approval from the institutional animal ethical committee of JJM Medical College, Davangere and CPCSEA. A total of 60 Swiss albino mice inbred in the Central Animal House of J.J.M.M.C of either sex and of weight between 20-40g and aged 3-4 months were taken for the study. They were divided into 10 groups of 6 animals each. The antidepressant activity of tramadol and tapentadol was evaluated in mice using forced swim test model and tail suspension test model.


In both the experimental models, Group i received normal saline- 10ml/kg(control group), group ii,iii,iv,v were given tramadol 20mg/kg, tramadol 40mg/kg, tapentadol 20mg/kg and tapentadol 40mg/kg respectively, once a day for 7 days. The drugs were given intraperitoneally.


On day 7, the drugs were given 1 hour before conducting the experiment. The duration of immobility was noted and compared amongst the 5 groups in both the models. The observations were analyzed using ANOVA (one way) and post hoc Tukey’s test. The test drugs tramadol and tapentadol showed significant reduction in duration of immobility in both the models. In FST model, tapentadol showed significant reduction in duration of immobility at the dose of 20mg/kg (34.67sec) when compared to 40mg/kg (67.5sec); (P <0.003) and was comparable to tramadol at a dose of 20mg/kg (36sec). In TST model, tapentadol at 20mg/kg has shown a greater reduction in duration of immobility (54.8sec) as compared to tramadol at 20mg/kg (106.17sec). Tapentadol showed a greater antidepressant activity compared to tramadol in TST model (P<0.001) and showed similar activity but was statistically insignificant.


Both tramadol and tapentadol have shown significant antidepressant activity in comparison with control group in both the test models. Tapentadol has shown better antidepressant activity than tramadol in TST model. Hence further animal studies with different model for depression and clinical studies should be conducted to confirm these findings and in choosing the better drug for treatment of chronic painful conditions like cancer which is often associated with depression.

Keywords

Antidepressant Tapentadol Tramadol

Article Details

How to Cite
Dr. Narendranath S, Dr. Shruthi K.S, & Dr. Pradeep B E. (2021). Comparative evaluation of antidepressant activity of tramadol and tapentadol in swiss albino mice. International Journal of Research in Pharmacology & Pharmacotherapeutics, 7(1), 40-48. Retrieved from https://ijrpp.com/ijrpp/article/view/233

References

  1. [1]. Benjamin J. Sadock, Virginia A. Sadock. (ed) Kaplan and Sadock’s Comprehensive text book of Psychiatry Philadelphia: Lippincott William & Wilkins; 1(8), 2004, 1625-1626.
  2. [2]. Anonymous, Depression, National Institute of Mental Health; [Online] Available from http://www.nimh.nih.gov/health/publications/depression/depression-booklet.pdf. Accessed on 2013.
  3. [3]. Gold PW, Goodwin FK, Chrousus GP. Clinical and Biochemical Manifestations of Depression In Relation To the Neurobiology of Stress, Part1. N Engl J Med. 319, 1988, 348-353.
  4. [4]. Harris NL. Chronic pain and depression. Aust Fam Physician. 28(1), 1999, 36-9
  5. [5]. Campbell L. C., Clauw D. J., Keefe F. J. Persistent pain and depression: a biopsychosocial perspective. Biol. Psychiatry 54, 2003, 399–409 10.1016/s0006-3223(03)00545-6
  6. [6]. Rojas-Corrales MO, Gibert-Rahola J, Mico JA. Tramadol induces antidepressant type effects in mice. Life Sci 63, 1998, 175-80.
  7. [7]. Tzschentke TM, Christoph T, Kögel B, Schiene K, Hennies HH, Englberger W, Haurand M, Jahnel U, Cremers TI, Friderichs E, De Vry J. (1R,2R)-3-(3- Dimethylamino-1-ethyl-2-methyl-propyl)- phenol Hydrochloride (Tapentadol HCl): a Novel μ-Opioid Receptor Agonist/Norepinephrine Reuptake Inhibitor with Broad-Spectrum Analgesic Properties. Journal of Pharmacology and Experimental Therapeutics. 23(1), 2007, 265-76.
  8. [8]. Wade WE, Spruill WJ. Tapentadol hydrochloride: a centrally acting oral analgesic. Clin Ther. 31(12), 2009, 2804–2818.
  9. [9]. Benjamin James Saddock, Virginia Alcott Sadock, Somatoform Disorders. In: Benjamin James Saddock, Virginia Alcott Sadock. Kaplan & Sadock’s synopsis of psychiatry. Lippincott Williams & Wilkins; 2007, 646-649.
  10. [10]. Ramakrishna S, GurusiddappaSK, Jambulingappa KL. A study of antinociceptive effect of venlafaxine in albino mice. Int J Basic ClinPharmacol 6, 2017, 184-8.
  11. [11]. Narendranath Sanji, Jyothi C.H., Dinakar K.R., Vidya H.K. Evaluation of Antidepressant Activity of Tramadol in Swiss Albino Mice Compared to Desipramine. International Journal of Pharma Research and Health Sciences. 3(1), 2015, 538-543.
  12. [12]. Porsolt RD. Animal models of depression: utility for transgenic research. Rev Neurosci 11(1), 2000, 52-8.
  13. [13]. Sirisha G, Rahul Prakash B, Usha Ns, Madhu Dhakhayani K. Evaluation of antidepressant effect of chronic administration of tramadol alone and in combination with fluoxetine in low doses in albino mice. Int J Pharm Pharm Sci 6(6), 2014, 101-105
  14. [14]. Chaudhary PK et al. Evaluation of antidepressant and analgesic activity of tapentadol with mirtazapine: an experimental study.Int J Basic Clin Pharmacol 4(3), 2015, 414-418.
  15. [15]. Srinivas KalyanaramanIyer, Gokulakrishnan Mohan, SivakumarRamakrishnan, and Sanjay Theodore. Comparison of tapentadol with tramadol for analgesia after cardiac surgery. Annals of Cardiac Anaesthesia. 18(3), 2015, 352–360.